A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma
Latest Information Update: 29 Jul 2024
At a glance
- Drugs INCB 099280 (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
Most Recent Events
- 26 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2023 Status changed from not yet recruiting to recruiting, as per a Incyte Corporation media release.
- 07 Jun 2023 New trial record